{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T02:18:51Z","timestamp":1790302731301,"version":"4.1.0"},"reference-count":115,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2013,10,1]],"date-time":"2013-10-01T00:00:00Z","timestamp":1380585600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2013,10,1]],"date-time":"2013-10-01T00:00:00Z","timestamp":1380585600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,8,22]],"date-time":"2023-08-22T00:00:00Z","timestamp":1692662400000},"content-version":"vor","delay-in-days":3612,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["neurotherapeuticsjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neurotherapeutics"],"published-print":{"date-parts":[[2013,10]]},"DOI":"10.1007\/s13311-013-0209-2","type":"journal-article","created":{"date-parts":[[2013,8,30]],"date-time":"2013-08-30T11:08:02Z","timestamp":1377860882000},"page":"677-687","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"title":["Applicability of Histone Deacetylase Inhibition for the Treatment of Spinal Muscular Atrophy"],"prefix":"10.1016","volume":"10","author":[{"given":"Sebastian","family":"Lunke","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Assam","family":"El-Osta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1007\/s13311-013-0209-2_bib1","doi-asserted-by":"crossref","first-page":"669","DOI":"10.2165\/00023210-200216100-00003","article-title":"Basic pharmacology of valproate: a review after 35 years of clinical use for the treatment of epilepsy","volume":"16","author":"Loscher","year":"2002","journal-title":"CNS Drugs"},{"key":"10.1007\/s13311-013-0209-2_bib2","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1016\/S0140-6736(80)90847-8","article-title":"Classification of spinal muscular atrophies","volume":"1","author":"Pearn","year":"1980","journal-title":"Lancet"},{"key":"10.1007\/s13311-013-0209-2_bib3","doi-asserted-by":"crossref","first-page":"695","DOI":"10.2165\/00023210-200216100-00004","article-title":"Pharmacological and therapeutic properties of valproate: a summary after 35 years of clinical experience","volume":"16","author":"Perucca","year":"2002","journal-title":"CNS Drugs"},{"key":"10.1007\/s13311-013-0209-2_bib4","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1086\/338627","article-title":"Quantitative analyses of SMN1 and SMN2 based on real-time lightCycler PCR: fast and highly reliable carrier testing and prediction of severity of spinal muscular atrophy","volume":"70","author":"Feldkotter","year":"2002","journal-title":"Am J Hum Genet"},{"key":"10.1007\/s13311-013-0209-2_bib5","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1001\/archneurpsyc.1956.02330230050005","article-title":"Heredofamilial juvenile muscular atrophy simulating muscular dystrophy","volume":"75","author":"Kugelberg","year":"1956","journal-title":"AMA Arch Neurol Psychiatry"},{"key":"10.1007\/s13311-013-0209-2_bib6","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1038\/sj.ejhg.5201102","article-title":"Phenylbutyrate increases SMN expression in vitro: relevance for treatment of spinal muscular atrophy","volume":"12","author":"Andreassi","year":"2004","journal-title":"Eur J Hum Genet"},{"key":"10.1007\/s13311-013-0209-2_bib7","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1016\/S0960-8966(06)80015-5","article-title":"International SMA consortium meeting (26\u201328 June 1992, Bonn, Germany)","volume":"2","author":"Munsat","year":"1992","journal-title":"Neuromuscul Disord"},{"key":"10.1007\/s13311-013-0209-2_bib8","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1111\/j.1471-4159.2006.03868.x","article-title":"In vitro and ex vivo evaluation of second-generation histone deacetylase inhibitors for the treatment of spinal muscular atrophy","volume":"98","author":"Hahnen","year":"2006","journal-title":"J Neurochem"},{"key":"10.1007\/s13311-013-0209-2_bib9","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1007\/s00439-006-0186-1","article-title":"The benzamide M344, a novel histone deacetylase inhibitor, significantly increases SMN2 RNA\/protein levels in spinal muscular atrophy cells","volume":"120","author":"Riessland","year":"2006","journal-title":"Hum Genet"},{"key":"10.1007\/s13311-013-0209-2_bib10","doi-asserted-by":"crossref","first-page":"1492","DOI":"10.1093\/hmg\/ddq023","article-title":"SAHA ameliorates the SMA phenotype in two mouse models for spinal muscular atrophy","volume":"19","author":"Riessland","year":"2010","journal-title":"Hum Mol Genet"},{"key":"10.1007\/s13311-013-0209-2_bib11","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1172\/JCI29562","article-title":"Trichostatin A increases SMN expression and survival in a mouse model of spinal muscular atrophy","volume":"117","author":"Avila","year":"2007","journal-title":"J Clin Invest"},{"key":"10.1007\/s13311-013-0209-2_bib12","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1097\/MOP.0b013e3282f1884c","article-title":"Clinical trials in spinal muscular atrophy","volume":"19","author":"Darras","year":"2007","journal-title":"Curr Opin Pediatr"},{"key":"10.1007\/s13311-013-0209-2_bib13","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1177\/0883073807305665","article-title":"Perspectives on clinical trials in spinal muscular atrophy","volume":"22","author":"Swoboda","year":"2007","journal-title":"J Child Neurol"},{"key":"10.1007\/s13311-013-0209-2_bib14","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1042\/BJ20070779","article-title":"Determination of the class and isoform selectivity of small-molecule histone deacetylase inhibitors","volume":"409","author":"Khan","year":"2008","journal-title":"Biochem J"},{"key":"10.1007\/s13311-013-0209-2_bib15","doi-asserted-by":"crossref","first-page":"3645","DOI":"10.1093\/hmg\/ddp313","article-title":"LBH589 induces up to 10-fold SMN protein levels by several independent mechanisms and is effective even in cells from SMA patients non-responsive to valproate","volume":"18","author":"Garbes","year":"2009","journal-title":"Hum Mol Genet"},{"key":"10.1007\/s13311-013-0209-2_bib16","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1001\/archneurol.2011.74","article-title":"Spinal muscular atrophy: a timely review","volume":"68","author":"Kolb","year":"2011","journal-title":"Arch Neurol"},{"key":"10.1007\/s13311-013-0209-2_bib17","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1007\/s11910-011-0240-9","article-title":"New therapeutic approaches to spinal muscular atrophy","volume":"12","author":"Lewelt","year":"2012","journal-title":"Curr Neurol Neurosci Rep"},{"key":"10.1007\/s13311-013-0209-2_bib18","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.molmed.2012.11.002","article-title":"Spinal muscular atrophy: going beyond the motor neuron","volume":"19","author":"Hamilton","year":"2013","journal-title":"Trends Mol Med"},{"key":"10.1007\/s13311-013-0209-2_bib19","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/0140-6736(90)91803-I","article-title":"Mapping of acute (type I) spinal muscular atrophy to chromosome 5q12-q14. The French Spinal Muscular Atrophy Investigators","volume":"336","author":"Melki","year":"1990","journal-title":"Lancet"},{"key":"10.1007\/s13311-013-0209-2_bib20","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1038\/344540a0","article-title":"Genetic mapping of chronic childhood-onset spinal muscular atrophy to chromosome 5q11.2-13.3","volume":"344","author":"Brzustowicz","year":"1990","journal-title":"Nature"},{"key":"10.1007\/s13311-013-0209-2_bib21","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1006\/geno.1993.1103","article-title":"Refined linkage map of chromosome 5 in the region of the spinal muscular atrophy gene","volume":"15","author":"Melki","year":"1993","journal-title":"Genomics"},{"key":"10.1007\/s13311-013-0209-2_bib22","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1159\/000472274","article-title":"el-Agwany A, Baasner A, et al. Mapping of the spinal muscular atrophy (SMA) gene to a 750-kb interval flanked by two new microsatellites","volume":"3","author":"Wirth","year":"1995","journal-title":"Eur J Hum Genet"},{"key":"10.1007\/s13311-013-0209-2_bib23","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1093\/hmg\/4.8.1273","article-title":"Allelic association and deletions in autosomal recessive proximal spinal muscular atrophy: association of marker genotype with disease severity and candidate cDNAs","volume":"4","author":"Wirth","year":"1995","journal-title":"Hum Mol Genet"},{"key":"10.1007\/s13311-013-0209-2_bib24","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/0092-8674(95)90460-3","article-title":"Identification and characterization of a spinal muscular atrophy-determining gene","volume":"80","author":"Lefebvre","year":"1995","journal-title":"Cell"},{"key":"10.1007\/s13311-013-0209-2_bib25","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/0092-8674(95)90461-1","article-title":"The gene for neuronal apoptosis inhibitory protein is partially deleted in individuals with spinal muscular atrophy","volume":"80","author":"Roy","year":"1995","journal-title":"Cell"},{"key":"10.1007\/s13311-013-0209-2_bib26","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1038\/ng0195-56","article-title":"A novel cDNA detects homozygous microdeletions in greater than 50% of type I spinal muscular atrophy patients","volume":"9","author":"Thompson","year":"1995","journal-title":"Nat Genet"},{"key":"10.1007\/s13311-013-0209-2_bib27","first-page":"805","article-title":"Deletions of the survival motor neuron gene in unaffected siblings of patients with spinal muscular atrophy","volume":"57","author":"Cobben","year":"1995","journal-title":"Am J Hum Genet"},{"key":"10.1007\/s13311-013-0209-2_bib28","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1002\/ana.410410214","article-title":"Deletion and conversion in spinal muscular atrophy patients: is there a relationship to severity?","volume":"41","author":"DiDonato","year":"1997","journal-title":"Ann Neurol"},{"key":"10.1007\/s13311-013-0209-2_bib29","doi-asserted-by":"crossref","first-page":"1927","DOI":"10.1093\/hmg\/4.10.1927","article-title":"Molecular analysis of candidate genes on chromosome 5q13 in autosomal recessive spinal muscular atrophy: evidence of homozygous deletions of the SMN gene in unaffected individuals","volume":"4","author":"Hahnen","year":"1995","journal-title":"Hum Mol Genet"},{"key":"10.1007\/s13311-013-0209-2_bib30","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1136\/jmg.33.6.469","article-title":"Unusual molecular findings in autosomal recessive spinal muscular atrophy","volume":"33","author":"Matthijs","year":"1996","journal-title":"J Med Genet"},{"key":"10.1007\/s13311-013-0209-2_bib31","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1093\/hmg\/4.4.631","article-title":"Deletions in the survival motor neuron gene on 5q13 in autosomal recessive spinal muscular atrophy","volume":"4","author":"Rodrigues","year":"1995","journal-title":"Hum Mol Genet"},{"key":"10.1007\/s13311-013-0209-2_bib32","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1093\/hmg\/5.2.257","article-title":"Molecular analysis of the SMN and NAIP genes in Spanish spinal muscular atrophy (SMA) families and correlation between number of copies of cBCD541 and SMA phenotype","volume":"5","author":"Velasco","year":"1996","journal-title":"Hum Mol Genet"},{"key":"10.1007\/s13311-013-0209-2_bib33","doi-asserted-by":"crossref","first-page":"1712","DOI":"10.1086\/302160","article-title":"Intragenic telSMN mutations: frequency, distribution, evidence of a founder effect, and modification of the spinal muscular atrophy phenotype by cenSMN copy number","volume":"63","author":"Parsons","year":"1998","journal-title":"Am J Hum Genet"},{"key":"10.1007\/s13311-013-0209-2_bib34","doi-asserted-by":"crossref","first-page":"1340","DOI":"10.1086\/302369","article-title":"Quantitative analysis of survival motor neuron copies: identification of subtle SMN1 mutations in patients with spinal muscular atrophy, genotype-phenotype correlation, and implications for genetic counseling","volume":"64","author":"Wirth","year":"1999","journal-title":"Am J Hum Genet"},{"key":"10.1007\/s13311-013-0209-2_bib35","doi-asserted-by":"crossref","first-page":"9920","DOI":"10.1073\/pnas.94.18.9920","article-title":"Inactivation of the survival motor neuron gene, a candidate gene for human spinal muscular atrophy, leads to massive cell death in early mouse embryos","volume":"94","author":"Schrank","year":"1997","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1007\/s13311-013-0209-2_bib36","doi-asserted-by":"crossref","first-page":"1411","DOI":"10.1086\/515465","article-title":"Identification of proximal spinal muscular atrophy carriers and patients by analysis of SMNT and SMNC gene copy number","volume":"60","author":"McAndrew","year":"1997","journal-title":"Am J Hum Genet"},{"key":"10.1007\/s13311-013-0209-2_bib37","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1006\/geno.1997.5141","article-title":"Sequence of a 131-kb region of 5q13.1 containing the spinal muscular atrophy candidate genes SMN and NAIP","volume":"48","author":"Chen","year":"1998","journal-title":"Genomics"},{"key":"10.1007\/s13311-013-0209-2_bib38","doi-asserted-by":"crossref","first-page":"6307","DOI":"10.1073\/pnas.96.11.6307","article-title":"A single nucleotide in the SMN gene regulates splicing and is responsible for spinal muscular atrophy","volume":"96","author":"Lorson","year":"1999","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1007\/s13311-013-0209-2_bib39","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1006\/bbrc.1995.2135","article-title":"Survival motor neuron gene transcript analysis in muscles from spinal muscular atrophy patients","volume":"213","author":"Gennarelli","year":"1995","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1007\/s13311-013-0209-2_bib40","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1038\/ng0598-63","article-title":"SMN oligomerization defect correlates with spinal muscular atrophy severity","volume":"19","author":"Lorson","year":"1998","journal-title":"Nat Genet"},{"key":"10.1007\/s13311-013-0209-2_bib41","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1093\/hmg\/6.8.1205","article-title":"The survival motor neuron protein in spinal muscular atrophy","volume":"6","author":"Coovert","year":"1997","journal-title":"Hum Mol Genet"},{"key":"10.1007\/s13311-013-0209-2_bib42","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1038\/ng0797-265","article-title":"Correlation between severity and SMN protein level in spinal muscular atrophy","volume":"16","author":"Lefebvre","year":"1997","journal-title":"Nat Genet"},{"key":"10.1007\/s13311-013-0209-2_bib43","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1007\/s00439-003-1025-2","article-title":"Evidence for a modifying pathway in SMA discordant families: reduced SMN level decreases the amount of its interacting partners and Htra2-beta1","volume":"114","author":"Helmken","year":"2003","journal-title":"Hum Genet"},{"key":"10.1007\/s13311-013-0209-2_bib44","doi-asserted-by":"crossref","first-page":"1492","DOI":"10.1096\/fj.06-7136com","article-title":"The spinal muscular atrophy gene product regulates neurite outgrowth: importance of the C terminus","volume":"21","author":"van Bergeijk","year":"2007","journal-title":"FASEB J"},{"key":"10.1007\/s13311-013-0209-2_bib45","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1086\/513913","article-title":"When is a deletion not a deletion? When it is converted","volume":"61","author":"Burghes","year":"1997","journal-title":"Am J Hum Genet"},{"key":"10.1007\/s13311-013-0209-2_bib46","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1086\/513886","article-title":"Genomic variation and gene conversion in spinal muscular atrophy: implications for disease process and clinical phenotype","volume":"61","author":"Campbell","year":"1997","journal-title":"Am J Hum Genet"},{"key":"10.1007\/s13311-013-0209-2_bib47","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1007\/s00439-006-0156-7","article-title":"Mildly affected patients with spinal muscular atrophy are partially protected by an increased SMN2 copy number","volume":"119","author":"Wirth","year":"2006","journal-title":"Hum Genet"},{"key":"10.1007\/s13311-013-0209-2_bib48","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1177\/0883073807305788","article-title":"Consensus statement for standard of care in spinal muscular atrophy","volume":"22","author":"Wang","year":"2007","journal-title":"J Child Neurol"},{"key":"10.1007\/s13311-013-0209-2_bib49","doi-asserted-by":"crossref","first-page":"5ra12","DOI":"10.1126\/scitranslmed.3000208","article-title":"Tetracyclines that promote SMN2 exon 7 splicing as therapeutics for spinal muscular atrophy","volume":"1","author":"Hastings","year":"2009","journal-title":"Sci Transl Med"},{"key":"10.1007\/s13311-013-0209-2_bib50","doi-asserted-by":"crossref","first-page":"2190","DOI":"10.1212\/WNL.0b013e3182020332","article-title":"Randomized, double-blind, placebo-controlled trial of hydroxyurea in spinal muscular atrophy","volume":"75","author":"Chen","year":"2010","journal-title":"Neurology"},{"key":"10.1007\/s13311-013-0209-2_bib51","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.jns.2007.11.012","article-title":"The effect of hydroxyurea in spinal muscular atrophy cells and patients","volume":"268","author":"Liang","year":"2008","journal-title":"J Neurol Sci"},{"key":"10.1007\/s13311-013-0209-2_bib52","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1212\/WNL.59.4.609","article-title":"Pilot trial of albuterol in spinal muscular atrophy","volume":"59","author":"Kinali","year":"2002","journal-title":"Neurology"},{"key":"10.1007\/s13311-013-0209-2_bib53","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1136\/jmg.2010.080366","article-title":"Salbutamol increases survival motor neuron (SMN) transcript levels in leucocytes of spinal muscular atrophy (SMA) patients: relevance for clinical trial design","volume":"47","author":"Tiziano","year":"2010","journal-title":"J Med Genet"},{"key":"10.1007\/s13311-013-0209-2_bib54","doi-asserted-by":"crossref","first-page":"1600","DOI":"10.1093\/hmg\/ddp076","article-title":"Delivery of bifunctional RNAs that target an intronic repressor and increase SMN levels in an animal model of spinal muscular atrophy","volume":"18","author":"Baughan","year":"2009","journal-title":"Hum Mol Genet"},{"key":"10.1007\/s13311-013-0209-2_bib55","doi-asserted-by":"crossref","first-page":"1471","DOI":"10.1038\/sj.mt.6300222","article-title":"Restoration of SMN function: delivery of a trans-splicing RNA re-directs SMN2 pre-mRNA splicing","volume":"15","author":"Coady","year":"2007","journal-title":"Mol Ther"},{"key":"10.1007\/s13311-013-0209-2_bib56","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1089\/hum.2008.067","article-title":"A negatively-acting bifunctional RNA increases survival motor neuron in vitro and in vivo","volume":"19","author":"Dickson","year":"2008","journal-title":"Hum Gene Ther"},{"key":"10.1007\/s13311-013-0209-2_bib57","doi-asserted-by":"crossref","first-page":"e73","DOI":"10.1371\/journal.pbio.0050073","article-title":"Enhancement of SMN2 exon 7 inclusion by antisense oligonucleotides targeting the exon","volume":"5","author":"Hua","year":"2007","journal-title":"PLoS Biol"},{"key":"10.1007\/s13311-013-0209-2_bib58","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1016\/j.ymthe.2005.08.022","article-title":"Correction of SMN2 Pre-mRNA splicing by antisense U7 small nuclear RNAs","volume":"12","author":"Madocsai","year":"2005","journal-title":"Mol Ther"},{"key":"10.1007\/s13311-013-0209-2_bib59","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1038\/sj.mt.6300200","article-title":"Spinal muscular atrophy: SMN2 pre-mRNA splicing corrected by a U7 snRNA derivative carrying a splicing enhancer sequence","volume":"15","author":"Marquis","year":"2007","journal-title":"Mol Ther"},{"key":"10.1007\/s13311-013-0209-2_bib60","doi-asserted-by":"crossref","first-page":"72ra18","DOI":"10.1126\/scitranslmed.3001777","article-title":"Antisense oligonucleotides delivered to the mouse CNS ameliorate symptoms of severe spinal muscular atrophy","volume":"3","author":"Passini","year":"2011","journal-title":"Sci Transl Med"},{"key":"10.1007\/s13311-013-0209-2_bib61","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1038\/nature10485","article-title":"Peripheral SMN restoration is essential for long-term rescue of a severe spinal muscular atrophy mouse model","volume":"478","author":"Hua","year":"2011","journal-title":"Nature"},{"key":"10.1007\/s13311-013-0209-2_bib62","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1038\/nbt.1610","article-title":"Rescue of the spinal muscular atrophy phenotype in a mouse model by early postnatal delivery of SMN","volume":"28","author":"Foust","year":"2010","journal-title":"Nat Biotechnol"},{"key":"10.1007\/s13311-013-0209-2_bib63","doi-asserted-by":"crossref","first-page":"35ra42","DOI":"10.1126\/scitranslmed.3000830","article-title":"Systemic delivery of scAAV9 expressing SMN prolongs survival in a model of spinal muscular atrophy","volume":"2","author":"Valori","year":"2010","journal-title":"Sci Transl Med"},{"key":"10.1007\/s13311-013-0209-2_bib64","doi-asserted-by":"crossref","first-page":"1726","DOI":"10.1172\/JCI22922","article-title":"Lentivector-mediated SMN replacement in a mouse model of spinal muscular atrophy","volume":"114","author":"Azzouz","year":"2004","journal-title":"J Clin Invest"},{"key":"10.1007\/s13311-013-0209-2_bib67","doi-asserted-by":"crossref","first-page":"165ra162","DOI":"10.1126\/scitranslmed.3004108","article-title":"Genetic correction of human induced pluripotent stem cells from patients with spinal muscular atrophy","volume":"4","author":"Corti","year":"2012","journal-title":"Sci Transl Med"},{"key":"10.1007\/s13311-013-0209-2_bib68","doi-asserted-by":"crossref","first-page":"201","DOI":"10.2217\/rme.11.6","article-title":"Stem cell technology for the study and treatment of motor neuron diseases","volume":"6","author":"Lunn","year":"2011","journal-title":"Regen Med"},{"key":"10.1007\/s13311-013-0209-2_bib69","doi-asserted-by":"crossref","first-page":"2913","DOI":"10.1111\/j.1460-9568.1998.00298.x","article-title":"Survival motor neuron (SMN) protein in rat is expressed as different molecular forms and is developmentally regulated","volume":"10","author":"La Bella","year":"1998","journal-title":"Eur J Neurosci"},{"key":"10.1007\/s13311-013-0209-2_bib70","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1093\/hmg\/ddi130","article-title":"The role of histone acetylation in SMN gene expression","volume":"14","author":"Kernochan","year":"2005","journal-title":"Hum Mol Genet"},{"key":"10.1007\/s13311-013-0209-2_bib71","doi-asserted-by":"crossref","first-page":"1961","DOI":"10.1093\/hmg\/6.11.1961","article-title":"Expression of the SMN gene, the spinal muscular atrophy determining gene, in the mammalian central nervous system","volume":"6","author":"Battaglia","year":"1997","journal-title":"Hum Mol Genet"},{"key":"10.1007\/s13311-013-0209-2_bib72","doi-asserted-by":"crossref","first-page":"1927","DOI":"10.1093\/hmg\/7.12.1927","article-title":"The distribution of SMN protein complex in human fetal tissues and its alteration in spinal muscular atrophy","volume":"7","author":"Burlet","year":"1998","journal-title":"Hum Mol Genet"},{"key":"10.1007\/s13311-013-0209-2_bib73","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1093\/hmg\/9.3.341","article-title":"Reduced survival motor neuron (Smn) gene dose in mice leads to motor neuron degeneration: an animal model for spinal muscular atrophy type III","volume":"9","author":"Jablonka","year":"2000","journal-title":"Hum Mol Genet"},{"key":"10.1007\/s13311-013-0209-2_bib74","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1038\/sj.ejhg.5201217","article-title":"Survival motor neuron SMN1 and SMN2 gene promoters: identical sequences and differential expression in neurons and non-neuronal cells","volume":"12","author":"Boda","year":"2004","journal-title":"Eur J Hum Genet"},{"key":"10.1007\/s13311-013-0209-2_bib75","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1002\/dvdy.21094","article-title":"Epigenetics in development","volume":"236","author":"Kiefer","year":"2007","journal-title":"Dev Dyn"},{"key":"10.1007\/s13311-013-0209-2_bib76","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/S0378-1119(01)00758-2","article-title":"The SMN genes are subject to transcriptional regulation during cellular differentiation","volume":"279","author":"Germain-Desprez","year":"2001","journal-title":"Gene"},{"key":"10.1007\/s13311-013-0209-2_bib77","doi-asserted-by":"crossref","first-page":"9808","DOI":"10.1073\/pnas.171105098","article-title":"Treatment of spinal muscular atrophy by sodium butyrate","volume":"98","author":"Chang","year":"2001","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1007\/s13311-013-0209-2_bib78","first-page":"3921","article-title":"Cholesteryl butyrate in solid lipid nanospheres as an alternative approach for butyric acid delivery","volume":"19","author":"Pellizzaro","year":"1999","journal-title":"Anticancer Res"},{"key":"10.1007\/s13311-013-0209-2_bib79","doi-asserted-by":"crossref","first-page":"2481","DOI":"10.1093\/hmg\/ddg256","article-title":"Valproic acid increases the SMN2 protein level: a well-known drug as a potential therapy for spinal muscular atrophy","volume":"12","author":"Brichta","year":"2003","journal-title":"Hum Mol Genet"},{"key":"10.1007\/s13311-013-0209-2_bib80","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1002\/ana.10743","article-title":"Valproic acid increases SMN levels in spinal muscular atrophy patient cells","volume":"54","author":"Sumner","year":"2003","journal-title":"Ann Neurol"},{"key":"10.1007\/s13311-013-0209-2_bib81","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1038\/sj.ejhg.5201102","article-title":"Phenylbutyrate increases SMN expression in vitro: relevance for treatment of spinal muscular atrophy","volume":"12","author":"Andreassi","year":"2003","journal-title":"Eur J Hum Genet"},{"key":"10.1007\/s13311-013-0209-2_bib82","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1146\/annurev.biochem.67.1.545","article-title":"Alteration of nucleosome structure as a mechanism of transcriptional regulation","volume":"67","author":"Workman","year":"1998","journal-title":"Annu Rev Biochem"},{"key":"10.1007\/s13311-013-0209-2_bib83","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1016\/j.cell.2007.01.015","article-title":"The role of chromatin during transcription","volume":"128","author":"Li","year":"2007","journal-title":"Cell"},{"key":"10.1007\/s13311-013-0209-2_bib84","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1093\/hmg\/ddi130","article-title":"The role of histone acetylation in SMN gene expression","volume":"14","author":"Kernochan","year":"2005","journal-title":"Hum Mol Genet"},{"key":"10.1007\/s13311-013-0209-2_bib85","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.bbrc.2011.09.011","article-title":"Differential regulation of the SMN2 gene by individual HDAC proteins","volume":"414","author":"Evans","year":"2011","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1007\/s13311-013-0209-2_bib86","doi-asserted-by":"crossref","first-page":"4408","DOI":"10.1074\/jbc.M606773200","article-title":"Cross-talk between histone modifications in response to histone deacetylase inhibitors: MLL4 links histone H3 acetylation and histone H3K4 methylation","volume":"282","author":"Nightingale","year":"2007","journal-title":"J Biol Chem"},{"key":"10.1007\/s13311-013-0209-2_bib87","doi-asserted-by":"crossref","first-page":"468","DOI":"10.4161\/cc.7.4.5405","article-title":"Effect of valproic acid on radiation-induced DNA damage in euchromatic and heterochromatic compartments","volume":"7","author":"Harikrishnan","year":"2008","journal-title":"Cell Cycle"},{"key":"10.1007\/s13311-013-0209-2_bib88","doi-asserted-by":"crossref","first-page":"1751","DOI":"10.1038\/sj.leu.2403910","article-title":"Histone deacetylases in acute myeloid leukaemia show a distinctive pattern of expression that changes selectively in response to deacetylase inhibitors","volume":"19","author":"Bradbury","year":"2005","journal-title":"Leukemia"},{"key":"10.1007\/s13311-013-0209-2_bib89","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1093\/carcin\/bgl167","article-title":"Valproate induces widespread epigenetic reprogramming which involves demethylation of specific genes","volume":"28","author":"Milutinovic","year":"2007","journal-title":"Carcinogenesis"},{"key":"10.1007\/s13311-013-0209-2_bib90","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.1016\/j.bcp.2006.12.032","article-title":"Histone deacetylase inhibitor Trichostatin A induces global and gene-specific DNA demethylation in human cancer cell lines","volume":"73","author":"Ou","year":"2007","journal-title":"Biochem. Pharmacol"},{"key":"10.1007\/s13311-013-0209-2_bib91","doi-asserted-by":"crossref","first-page":"27586","DOI":"10.1074\/jbc.M303740200","article-title":"Valproate induces replication-independent active DNA demethylation","volume":"278","author":"Detich","year":"2003","journal-title":"J Biol Chem"},{"key":"10.1007\/s13311-013-0209-2_bib92","doi-asserted-by":"crossref","first-page":"40778","DOI":"10.1074\/jbc.M103921200","article-title":"Demethylase activity is directed by histone acetylation","volume":"276","author":"Cervoni","year":"2001","journal-title":"J Biol Chem"},{"key":"10.1007\/s13311-013-0209-2_bib93","doi-asserted-by":"crossref","first-page":"25026","DOI":"10.1074\/jbc.M202256200","article-title":"The oncoprotein Set\/TAF-1beta, an inhibitor of histone acetyltransferase, inhibits active demethylation of DNA, integrating DNA methylation and transcriptional silencing","volume":"277","author":"Cervoni","year":"2002","journal-title":"J Biol Chem"},{"key":"10.1007\/s13311-013-0209-2_bib94","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1016\/j.cell.2010.08.011","article-title":"The language of histone crosstalk","volume":"142","author":"Lee","year":"2010","journal-title":"Cell"},{"key":"10.1007\/s13311-013-0209-2_bib95","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1042\/BC20110028","article-title":"Histone demethylases in chromatin cross-talks","volume":"103","author":"Verrier","year":"2011","journal-title":"Biol. Cell"},{"key":"10.1007\/s13311-013-0209-2_bib96","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1016\/j.cell.2008.10.036","article-title":"Crosstalk among histone modifications","volume":"135","author":"Suganuma","year":"2008","journal-title":"Cell"},{"key":"10.1007\/s13311-013-0209-2_bib97","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1002\/(SICI)1096-9926(199612)54:6<284::AID-TERA3>3.0.CO;2-Z","article-title":"Valproic acid-induced changes in gene expression during neurulation in a mouse model","volume":"54","author":"Wlodarczyk","year":"1996","journal-title":"Teratology"},{"key":"10.1007\/s13311-013-0209-2_bib98","doi-asserted-by":"crossref","first-page":"17785","DOI":"10.1074\/jbc.M209430200","article-title":"Sp family of transcription factors is involved in valproic acid-induced expression of Galphai2","volume":"278","author":"Arinze","year":"2003","journal-title":"J Biol Chem"},{"key":"10.1007\/s13311-013-0209-2_bib99","doi-asserted-by":"crossref","first-page":"9808","DOI":"10.1073\/pnas.171105098","article-title":"Treatment of spinal muscular atrophy by sodium butyrate","volume":"98","author":"Chang","year":"2001","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1007\/s13311-013-0209-2_bib100","doi-asserted-by":"crossref","first-page":"9618","DOI":"10.1073\/pnas.160181697","article-title":"Htra2-beta 1 stimulates an exonic splicing enhancer and can restore full-length SMN expression to survival motor neuron 2 (SMN2)","volume":"97","author":"Hofmann","year":"2000","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1007\/s13311-013-0209-2_bib101","doi-asserted-by":"crossref","first-page":"3697","DOI":"10.1073\/pnas.0500369102","article-title":"Identification and functional significance of genes regulated by structurally different histone deacetylase inhibitors","volume":"102","author":"Peart","year":"2005","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1007\/s13311-013-0209-2_bib102","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1038\/nrc1779","article-title":"Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer","volume":"6","author":"Minucci","year":"2006","journal-title":"Nat Rev Cancer"},{"key":"10.1007\/s13311-013-0209-2_bib103","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1038\/nrd2133","article-title":"Anticancer activities of histone deacetylase inhibitors","volume":"5","author":"Bolden","year":"2006","journal-title":"Nat Rev Drug Discov"},{"key":"10.1007\/s13311-013-0209-2_bib104","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1136\/jnnp.2009.200253","article-title":"Quantification of SMN protein in leucocytes from spinal muscular atrophy patients: effects of treatment with valproic acid","volume":"82","author":"Piepers","year":"2011","journal-title":"J Neurol Neurosurg Psychiatr"},{"key":"10.1007\/s13311-013-0209-2_bib105","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1002\/ana.20836","article-title":"In vivo activation of SMN in spinal muscular atrophy carriers and patients treated with valproate","volume":"59","author":"Brichta","year":"2006","journal-title":"Ann Neurol"},{"key":"10.1007\/s13311-013-0209-2_bib106","doi-asserted-by":"crossref","first-page":"e8","DOI":"10.1111\/j.1468-1331.2007.01992.x","article-title":"Valproic acid treatment in six patients with spinal muscular atrophy","volume":"14","author":"Tsai","year":"2007","journal-title":"Eur J Neurol"},{"key":"10.1007\/s13311-013-0209-2_bib107","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1212\/01.wnl.0000231139.26253.d0","article-title":"Valproate may improve strength and function in patients with type III\/IV spinal muscle atrophy","volume":"67","author":"Weihl","year":"2006","journal-title":"Neurology"},{"key":"10.1007\/s13311-013-0209-2_bib108","doi-asserted-by":"crossref","first-page":"e21296","DOI":"10.1371\/journal.pone.0021296","article-title":"SMA CARNIVAL TRIAL PART II: a prospective, single-armed trial of L-carnitine and valproic acid in ambulatory children with spinal muscular atrophy","volume":"6","author":"Kissel","year":"2011","journal-title":"PLoS ONE"},{"key":"10.1007\/s13311-013-0209-2_bib109","doi-asserted-by":"crossref","first-page":"e12140","DOI":"10.1371\/journal.pone.0012140","article-title":"SMA CARNI-VAL trial part I: double-blind, randomized, placebo-controlled trial of L-carnitine and valproic acid in spinal muscular atrophy","volume":"5","author":"Swoboda","year":"2010","journal-title":"PLoS ONE"},{"key":"10.1007\/s13311-013-0209-2_bib110","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1038\/sj.ejhg.5201320","article-title":"Phenylbutyrate increases SMN gene expression in spinal muscular atrophy patients","volume":"13","author":"Brahe","year":"2004","journal-title":"Eur J Hum Genet"},{"key":"10.1007\/s13311-013-0209-2_bib111","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.nmd.2003.11.006","article-title":"Pilot trial of phenylbutyrate in spinal muscular atrophy","volume":"14","author":"Mercuri","year":"2004","journal-title":"Neuromuscul Disord"},{"key":"10.1007\/s13311-013-0209-2_bib112","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1212\/01.wnl.0000249142.82285.d6","article-title":"Randomized, double-blind, placebo-controlled trial of phenylbutyrate in spinal muscular atrophy","volume":"68","author":"Mercuri","year":"2007","journal-title":"Neurology"},{"key":"10.1007\/s13311-013-0209-2_bib113","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.pediatrneurol.2011.09.001","article-title":"Spinal muscular atrophy: a clinical and research update","volume":"46","author":"Markowitz","year":"2012","journal-title":"Pediatr Neurol"},{"key":"10.1007\/s13311-013-0209-2_bib114","doi-asserted-by":"crossref","first-page":"e5268","DOI":"10.1371\/journal.pone.0005268","article-title":"Phase II open label study of valproic acid in spinal muscular atrophy","volume":"4","author":"Swoboda","year":"2009","journal-title":"PLoS ONE"},{"key":"10.1007\/s13311-013-0209-2_bib115","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1002\/(SICI)1096-9926(199612)54:6<284::AID-TERA3>3.0.CO;2-Z","article-title":"Valproic acid-induced changes in gene expression during neurulation in a mouse model","volume":"54","author":"Wlodarczyk","year":"1996","journal-title":"Teratology"},{"key":"10.1007\/s13311-013-0209-2_bib116","doi-asserted-by":"crossref","first-page":"17785","DOI":"10.1074\/jbc.M209430200","article-title":"Sp family of transcription factors is involved in valproic acid-induced expression of Galphai2","volume":"278","author":"Arinze","year":"2003","journal-title":"J Biol Chem"},{"key":"10.1007\/s13311-013-0209-2_bib117","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1093\/hmg\/ddn357","article-title":"Survival motor neuron gene 2 silencing by DNA methylation correlates with spinal muscular atrophy disease severity and can be bypassed by histone deacetylase inhibition","volume":"18","author":"Hauke","year":"2009","journal-title":"Hum Mol Genet"}],"container-title":["Neurotherapeutics"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s13311-013-0209-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s13311-013-0209-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1878747923016628?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1878747923016628?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s13311-013-0209-2","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T07:07:19Z","timestamp":1761808039000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1878747923016628"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,10]]},"references-count":115,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2013,10]]}},"alternative-id":["S1878747923016628"],"URL":"https:\/\/doi.org\/10.1007\/s13311-013-0209-2","relation":{},"ISSN":["1878-7479"],"issn-type":[{"value":"1878-7479","type":"print"}],"subject":[],"published":{"date-parts":[[2013,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Applicability of Histone Deacetylase Inhibition for the Treatment of Spinal Muscular Atrophy","name":"articletitle","label":"Article Title"},{"value":"Neurotherapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1007\/s13311-013-0209-2","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2013 The American Society for Experimental NeuroTherapeutics, Inc. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}